Search
Prothena Corporation PLC
PRTAAdd to Watchlist
9.675USD
-0.185-1.88%
Market hours （ET）Quotes delayed by 15 min
513.52MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.88%
5 Days
-8.03%
1 Month
-8.81%
6 Months
-2.57%
Year to Date
+1.31%
1 Year
+40.52%
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2026-05-14Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 94 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.40.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Fairly Valued
The company’s latest PE is -3.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.39M shares, decreasing 22.37% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.73K shares of this stock.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+122.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prothena Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEOKinney (Gene G)
Websitehttps://www.prothena.com/
Related Instruments
-0.76%
-1.81%
-0.94%
-0.45%
-1.09%
-1.65%
-2.14%
-2.00%
-2.87%
-1.46%
-0.46%
-2.92%
+0.11%
-2.66%
+1.48%
0.00%
-1.93%
-0.09%
-1.97%
-0.11%Popular Instruments
101.360
+2.497 (+2.53%)
302.400
+4.190 (+1.41%)
228.010
-7.730 (-3.28%)
4556.590
-93.640 (-2.01%)
479.940
-9.210 (-1.88%)
1397.825
+15.105 (+1.09%)
738.335
-37.675 (-4.86%)
396.620
-4.450 (-1.11%)
79245.520
-2136.520 (-2.63%)
425.450
-17.850 (-4.03%)
